Jonathan R. Strosberg
Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.
Overview
Jonathan Strosberg was principal investigator of NETTER-1, which showed 177Lu-DOTATATE reduces the risk of progression by 79% in midgut neuroendocrine tumours and led to Lutathera's approval, the first radioligand therapy approved for a solid tumour and the template for PSMA-targeted therapy. He co-leads the NETTER-2 and COMPETE programmes and chairs the North American Neuroendocrine Tumor Society guidelines.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
People treated with the radioactive drug lutetium-177 dotatate kept feeling well for much longer - years rather than months, in several measures - than people on the standard high-dose hormone injection, on top of the tumour-control benefit already shown.
Similar pages
not linked directly; found by shared links- PersonSimron Singh
Shares NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours and the tags neuroendocrine, radioligand.
- PersonEmily K. Bergsland
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonA. Oliver Sartor
Shares Radioligand therapy (beta emitters), Lutetium-177 and the tags radioligand, trialist.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- IndicationGrade 3 well-differentiated neuroendocrine tumour
Shares COMPETE, NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours, Somatostatin receptor 2, Lutetium-177 dotatate.
- InstitutionErasmus MC Cancer Institute
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonKen Herrmann
Shares Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters), Lutetium-177 and the tag radioligand.